Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group [PDF]
, 2021 Morten Magelssen +3 more
openalex +1 more source
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients [PDF]
, 2021 Iddo Magen +11 more
openalex +1 more source
ND2 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT [PDF]
, 2019 Daniel C. Malone +8 more
openalex +1 more source
4CPS-131 Effectiveness of nusinersen in paediatric patients SMA1 and SMA2 [PDF]
, 2020 GB Ortenzi +10 more
openalex +1 more source
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy [PDF]
, 2021 Sheridan M. Hoy
openalex +1 more source
PND9 EVENT-FREE SURVIVAL AND MOTOR MILESTONE ACHIEVEMENT FOLLOWING AVXS-101 AND NUSINERSEN INTERVENTIONS CONTRASTED TO NATURAL HISTORY FOR TYPE I SPINAL MUSCULAR ATROPHY PATIENTS [PDF]
, 2019 Omar Dabbous +8 more
openalex +1 more source
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data [PDF]
, 2022 Judit Erdös, Claudia Wild
openalex +1 more source
Stabilization of Respiratory Function in Pediatric Spinal Muscular Atrophy Treated with Nusinersen [PDF]
, 2020 Archana Chacko +3 more
openalex +1 more source
Development and validation of an HILIC/MS/MS method for determination of nusinersen in rabbit plasma
HeliyonA hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC/MS/MS) method was developed and validated for the quantitative analysis of the fully phosphorothioate modified oligonucleotide nusinersen.
Xiao Zhang +6 more
doaj
Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy [PDF]
, 2022 Rotem Orbach +6 more
openalex +1 more source